Ribavirin is a nucleoside analogue that mimics the nucleoside guanosine. It shows some activity against a broad range of DNA and RNA viruses, but is less effective against dengue fever, yellow fever and other flaviviruses. The drug was first synthesised in the early 1970s by Joseph T. Witkowski and Roland K. Robins. Ribavirin's main current use is against hepatitis C, in combination with pegylated interferon, nucleotide analogues and protease inhibitors. It has been used in the past in an aerosol formulation against respiratory syncytial virus-related diseases in children. Ribavirin has been used in combination as part of an experimental treatment for rabies. It is also the only available treatment for the viruses causing some viral haemorrhagic fevers, including Lassa fever, Crimean–Congo haemorrhagic fever and hantavirus disease, but is ineffective against the filovirus diseases, Ebola and Marburg. Clinical use is limited by the drug building up in red blood cells to cause haemolytic anaemia.